Drug Discovery Consortia: Bringing New, Biologically Rational Targets to the ALS Clinical Pipeline
Expire le 17 juin 2025
While new therapeutics targeting causative genetic mutations have begun moving the needle for some people with ALS, other candidate therapeutics targeting specific cellular pathways and pathology have been less successful in clinical trials. Target ALS seeks to incentivize collaborations between academia and biotechnology/pharmaceutical companies that broaden the landscape of candidate ALS therapeutics strongly rooted in a deep biological understanding of the disease. We are soliciting proposals from collaborative groups focused on the discovery of novel therapeutic targets with strong potential for translation into the clinical pipeline.